Company Omni Bio Pharmaceutical, Inc.

Equities

OMBP

US68216L1008

Biotechnology & Medical Research

Business Summary

Share class

Company contact information

Sector

Sector Bio Therapeutic Drugs

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+66.67%	+233.33%

2016	Omni Bio Pharmaceutical, Inc. cancelled the transaction announced on March 16, 2015	CI
2015	Omni Bio Pharmaceutical, Inc. Announces Management Changes	CI

Omni Bio Pharmaceutical, Inc. is a United States-based company that operates as a biopharmaceutical company. The Company is focused on the treatment of immune-mediated inflammatory disease. The Company is providing recombinant version of plasma-derived alpha-1 antitrypsin (p-AAT) platform for intravenous supplementation therapy.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	40,462,602	40,462,602 ( 100.00 %)	0	100.00 %

Omni Bio Pharmaceutical, Inc.

181 West Boardwalk Drive Suite 202

80525, Fort Collins

http://omnibiopharma.com

address Omni Bio Pharmaceutical, Inc.(OMBP)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
OMNI BIO PHARMACEUTICAL, INC.	+233.33%	50.06K
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs